Drug-eluting stents for treatment of coronary artery disease
HAYES, Inc.
Record ID 32004000395
English
Authors' objectives:
Drug-eluting stents are used for the minimally invasive treatment of coronary artery obstruction in patients with symptomatic coronary artery disease (CAD) who require percutaneous transluminal coronary angioplasty (PTCA) and stenting. A drug-eluting stent is a bare-metal stent that is coated with an antiproliferative drug, which is released gradually into the arterial wall to suppress scar tissue formation within the stent and adjacent areas. The goals of treatment are to reduce the incidence of instent restenosis, symptom recurrence, and other complications, and thereby reduce the need for repeat percutaneous or surgical revascularization.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Coronary Artery Disease
- Drug Delivery Systems
- Stents
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.